Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody

Autor: Angèle L.M. Oei, André J. Olthaar, Leon F.A.G. Massuger, Chris M.G. Thomas, Fred C.G.J. Sweep
Rok vydání: 2008
Předmět:
medicine.medical_specialty
Time Factors
medicine.drug_class
Aetiology
screening and detection [ONCOL 5]
Pharmacology
Monoclonal antibody
Chromatography
Affinity
Mice
Thyroid-stimulating hormone
Affinity chromatography
Translational research [ONCOL 3]
Internal medicine
medicine
Animals
Humans
Drug Interactions
Murine monoclonal antibody
Glycoproteins
Molecular diagnosis
prognosis and monitoring [UMCN 1.2]
Ovarian Neoplasms
biology
Hereditary cancer and cancer-related syndromes [ONCOL 1]
business.industry
Endocrinology and reproduction [UMCN 5.2]
Standard treatment
Osmolar Concentration
Hormonal regulation [IGMD 6]
Obstetrics and Gynecology
Antibodies
Monoclonal
Fast protein liquid chromatography
Immunotherapy
gene therapy and transplantation [UMCN 1.4]
Lipid Droplets
medicine.disease
Endocrinology
Oncology
CA-125 Antigen
Population Surveillance
biology.protein
Female
Antibody
Glycolipids
business
Ovarian cancer
Injections
Intraperitoneal
Zdroj: Gynecologic Oncology, 109, 2, pp. 199-202
Gynecologic Oncology, 109, 199-202
ISSN: 0090-8258
Popis: Contains fulltext : 70582.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To investigate the influence of human anti-mouse antibodies (HAMA) on serial CA 125 measurements in serum of patients with epithelial ovarian cancer following single intraperitoneal (IP) therapy with Yttrium-90-labeled human milk fat globule 1 murine monoclonal antibody ((90)Y-muHMFG1) as part of a large international randomized phase III trial. METHODS: We monitored CA 125 concentrations in longitudinally collected serum samples from 224 patients after IP (90)Y-muHMFG1 (study group) and from 223 patients who received standard treatment (control group). Serum samples of 22 study patients with increased CA 125 concentrations were selected and subjected to affinity chromatography to study HAMA interference in CA 125 measurements. RESULTS: CA 125 serum concentrations at weeks 1, 4 and 8 were significantly higher in the study group than in the control group. In the first 8 weeks after IP (90)Y-muHMFG1 administration significantly more patients of the study group (144/224) demonstrated CA 125 concentrations above the upper limit of normal of 23 U/mL, as compared to those of the control group (37/223). Affinity chromatography of serum with high CA 125 values in the first 8 weeks confirmed HAMA interference in CA 125 measurements while after 24 weeks this HAMA interference could no longer be detected. CONCLUSIONS: This is the first study to demonstrate that clinical trials applying murine monoclonal antibodies may be flawed by a transient HAMA effect, which should be considered when monitoring ovarian cancer patients with CA 125 measurements.
Databáze: OpenAIRE
Externí odkaz: